|
| CAMH Clinical Trial on Aripiprazole Aripiprazole, a new antipsychotic drug made by Bristol-Meyers Squibb, is now being tested in Toronto's notorious Centre for Addiction & Mental Health (CAMH) to see if it's more effective then Perphanazine. The study is being conducted by Dr Roy McCurley and co-investigator Dr. Pablo Diaz. The 'study coordinator' is Hesther Tims. The CAMH tel# 416-535-8501 - McCurley's ext. 2121, Diaz's ext. 2743, Tims' ext. 2062. Here's the opening statement on the PR News release:
CAMH has been accused by the antipsychiatry movement of incompetent and biased research heavily funded by drug companies. A few months ago, the University of Toronto and CAMH refused to hire biopsychiatrist-researcher David Healy who committed the crime of simply stating in a public lecture last winter that Prozac can make people more depressed or suicidal - a well-documented, widely-known fact during the last 10 years! (Click here for article) |
|
Opinions expressed in this web site do not necessarily reflect the views of NAMI Santa Cruz County, NAMI California or any affiliated organizations. We attempt to present a balanced perspective on issues by presenting multiple viewpoints. Copyright 2005 National Alliance for the Mentally Ill Santa Cruz County, All Rights Reserved. FAIR USE NOTICE: This may contain copyrighted (©) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available to advance understanding of ecological, political, human rights, economic, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml If you wish to use copyrighted material for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner. |